Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A4-TCR
- Development stage
- Unknown
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A4-TCR is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the Melanoma-Associated Antigen A4 (MAGE-A4), a cancer-testis antigen frequently expressed in various solid tumors. The TCR was discovered using Medigene's proprietary platform and was initially licensed to 2seventy bio before being acquired by Regeneron Pharmaceuticals in April 2024. The therapy works by modifying a patient's own T cells to express a specific TCR that recognizes MAGE-A4 peptides presented by HLA molecules on tumor cells, leading to targeted cell killing. It is currently in early-stage clinical development for the treatment of solid tumors, with specific trials being conducted in China through a partnership with JW Therapeutics.
- Other names
- MAGE-A4 TCR programMAGE-A-4 TCR programMAGE-A 4 TCR programMedigene MAGE-A4 TCR
02
Targets
MAGE-A4 peptide-HLA-A*02:01 complex
Beyond the preview
Go deeper on MAGE-A4-TCR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A4-TCR.